CompletedNCT02075528
Official study titleEarly Prediction of Clinical Response, Metabolic Change, and Pharmacokinetics in Taiwanese Patients With Schizophrenia Patients Treated by Paliperidone ER: an Open-Label Study
This study has finished and is no longer accepting participants.
In TaipeiSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- Taipei City Hospital
CompletedNCT00646581
Official study titleEffect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In BostonSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- University of Massachusetts, Worcester
CompletedNCT01093365
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaMedication studyAges 18–55
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT01780116
Official study titleAn Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial
This study has finished and is no longer accepting participants.
Multiple locations, including Kwai ChungSchizophreniaBehavioural studyAges 18–65
- Countries
- China
- Sponsor
- The Hong Kong Polytechnic University
CompletedNCT05805397
Official study titleMotivation Skills Training to Enhance Functional Outcomes for People With Schizophrenia
This study has finished and is no longer accepting participants.
In New YorkSchizophreniaBehavioural studyAges 18–65
- Countries
- United States
- Sponsor
- Columbia University
CompletedNCT01043250
Official study titleEffects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain
This study has finished and is no longer accepting participants.
In SeoulSchizophreniaObservational studyAges 19–59
- Countries
- South Korea
- Sponsor
- Samsung Medical Center
CompletedNCT00057707
Official study titleRandomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
This study has finished and is no longer accepting participants.
In BethesdaSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
CompletedNCT00148083
Official study titleEfficacy of Risperidone Consta for Improving Ability to Benefit From Skills Training in Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including ChicagoSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- University of Illinois Chicago
CompletedNCT00231335
What is this study about?This study evaluated the safety and effectiveness of escitalopram for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Emory University
CompletedNCT00615511
Official study titleEfficacy of Pregnenolone in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including PiscatawaySchizophreniaPlacebo comparisonAges 18–65
- Countries
- United States
- Sponsor
- Weill Medical College of Cornell University
CompletedNCT00337662
What is this study about?Researchers compared olanzapine and risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States, Argentina, Russia
- Sponsor
- Eli Lilly and Company
CompletedNCT00176423
Official study titleAdjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore